DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. reduced its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 7.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 139,800 shares of the medical device company's stock after selling 10,800 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in DexCom were worth $9,547,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Proficio Capital Partners LLC acquired a new position in DexCom during the 4th quarter worth approximately $5,812,000. SBI Securities Co. Ltd. purchased a new stake in shares of DexCom in the fourth quarter valued at approximately $49,000. Van ECK Associates Corp grew its holdings in DexCom by 325.0% during the fourth quarter. Van ECK Associates Corp now owns 85,813 shares of the medical device company's stock worth $6,674,000 after acquiring an additional 65,622 shares during the period. Allspring Global Investments Holdings LLC raised its position in DexCom by 28.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 58,571 shares of the medical device company's stock worth $4,596,000 after acquiring an additional 13,111 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its holdings in DexCom by 45.5% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 55,752 shares of the medical device company's stock valued at $4,336,000 after acquiring an additional 17,435 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Nicholas Augustinos sold 2,618 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $81.69, for a total value of $213,864.42. Following the sale, the director now owns 37,083 shares of the company's stock, valued at approximately $3,029,310.27. The trade was a 6.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,474 shares of company stock worth $1,887,026 in the last three months. Company insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent analyst reports. Piper Sandler lowered their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Citigroup restated a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Mizuho assumed coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target on the stock. Finally, The Goldman Sachs Group initiated coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Trading Down 0.5%

DXCM traded down $0.41 during trading on Wednesday, hitting $81.42. The company's stock had a trading volume of 488,185 shares, compared to its average volume of 4,329,212. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.49. The stock has a market cap of $31.92 billion, a PE ratio of 60.76, a PEG ratio of 1.77 and a beta of 1.46. The firm's 50 day moving average price is $79.25 and its 200-day moving average price is $79.38. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the company posted $0.32 earnings per share. The business's quarterly revenue was up 12.5% compared to the same quarter last year. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.